Welcome to our dedicated page for Agenus news (Ticker: AGEN), a resource for investors and traders seeking the latest updates and insights on Agenus stock.
Agenus Inc. develops immuno-oncology therapies for cancer, with recurring updates centered on botensilimab (BOT) and balstilimab (BAL), its CTLA-4/PD-1 immunotherapy combination. Company news regularly covers clinical data in solid tumors, including metastatic colorectal cancer, melanoma and gastroesophageal cancer, as well as translational biomarker work and combination approaches that use antibody therapeutics, adoptive cell therapy through MiNK Therapeutics and adjuvants.
Agenus updates also address regulatory-authorized access pathways for BOT+BAL, including France's AAC framework and paid named-patient programs where permitted, along with financial results, equity financing activity, commercial readiness, manufacturing collaborations and corporate governance developments.
Agenus Inc. (NASDAQ: AGEN) has announced it will host its 2020 Annual Shareholders Meeting virtually on June 16, 2020, at 5:00 PM ET due to COVID-19 concerns. Shareholders can log in starting at 4:30 PM ET using a 16-digit control number provided in proxy materials. Guests may join in listen-only mode. The meeting can be accessed via the company's website or directly through the virtual meeting link. A replay will be available for one year post-event. Agenus focuses on immuno-oncology therapy development to enhance cancer treatment.